Merck & Co., Inc. (MRK)

MRK Financials

MRK Quarterly Income Statement (USD)

Quarterly Report	TTM	03/31/2026	12/31/2025	09/30/2025	06/30/2025	03/31/2025	12/31/2024	09/30/2024	06/30/2024
Gross Profit	49.791B	13.342B	11.507B	12.989B	11.953B	11.734B	11.796B	12.577B	12.367B
Revenue	65.593B	16.286B	16.324B	17.183B	15.800B	15.619B	15.624B	16.657B	16.112B
Cost of Goods Sold	15.802B	2.944B	4.817B	4.194B	3.847B	3.885B	3.828B	4.080B	3.745B
Gross Profit Margin	81.9%	81.9%	70.5%	75.6%	75.7%	75.1%	75.5%	75.5%	76.8%
Total Operating Expenses	31.693B	15.226B	5.347B	5.526B	5.594B	5.024B	7.448B	8.593B	6.239B
Research & Development	22.149B	12.558B	2.499B	3.552B	3.540B	3.119B	4.584B	5.862B	3.500B
Selling, General & Administrative	9.544B	2.668B	2.848B	1.974B	2.054B	1.905B	2.691B	2.731B	2.739B
Operating Income (EBIT)	18.098B	-1.884B	6.160B	7.463B	6.359B	6.710B	4.348B	3.984B	6.128B
Operating Margin	-11.6%	-11.6%	37.7%	43.4%	40.2%	43.0%	27.8%	23.9%	38.0%
Income Before Tax (EBT)	11.630B	-3.534B	3.420B	6.745B	4.999B	5.903B	4.170B	4.090B	6.006B
Interest Income	234.000M	—	69.000M	96.000M	69.000M	109.000M	146.000M	127.000M	69.000M
Interest Expense	1.043B	—	411.000M	327.000M	305.000M	313.000M	328.000M	330.000M	310.000M
Other Income/Expense	-6.468B	-1.650B	-2.740B	-718.000M	-1.360B	-807.000M	-178.000M	106.000M	-122.000M
Net Income	8.935B	-4.240B	2.963B	5.785B	4.427B	5.079B	3.743B	3.157B	5.455B
Income Tax Expense	2.696B	709.000M	458.000M	958.000M	571.000M	818.000M	426.000M	929.000M	545.000M
Net Profit Margin	-26.0%	-26.0%	18.2%	33.7%	28.0%	32.5%	24.0%	19.0%	33.9%
EBITDA	22.692B	-1.884B	8.626B	8.535B	7.415B	7.809B	5.695B	5.606B	7.448B
EBITDA Margin	-11.6%	-11.6%	52.8%	49.7%	46.9%	50.0%	36.5%	33.7%	46.2%
Depreciation & Amortization	4.594B	0.00	2.466B	1.072B	1.056B	1.099B	1.197B	1.186B	1.132B
EPS Basic	3.56	-1.72	1.20	2.32	1.76	2.01	1.48	1.25	2.15
EPS Diluted	3.55	-1.72	1.19	2.32	1.76	2.01	1.48	1.24	2.14
Shares Outstanding	2.472B	2.472B	2.475B	2.495B	2.510B	2.523B	2.541B	2.541B	2.534B
Diluted Shares Outstanding	2.472B	2.472B	2.488B	2.498B	2.513B	2.531B	2.541B	2.541B	2.544B

MRK Annual Income Statement (USD)

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Gross Profit	46.731B	48.975B	43.989B	41.872B	35.078B	27.900B	27.105B	28.785B
Revenue	64.926B	64.168B	60.115B	59.283B	48.704B	41.518B	39.121B	42.294B
Cost of Goods Sold	18.195B	15.193B	16.126B	17.411B	13.626B	13.618B	12.016B	13.509B
Gross Profit Margin	72.0%	76.3%	73.2%	70.6%	72.0%	67.2%	69.3%	68.1%
Total Operating Expenses	23.245B	28.754B	41.035B	23.590B	21.879B	22.352B	19.179B	19.854B
Research & Development	12.514B	17.938B	30.531B	13.548B	12.245B	13.397B	9.724B	9.752B
Selling, General & Administrative	10.731B	10.100B	9.884B	9.669B	9.403B	8.569B	9.455B	10.102B
Operating Income (EBIT)	23.486B	20.221B	2.954B	18.282B	13.199B	5.548B	7.926B	8.931B
Operating Margin	36.2%	31.5%	4.9%	30.8%	27.1%	13.4%	20.3%	21.1%
Income Before Tax (EBT)	21.067B	19.936B	1.889B	16.444B	13.879B	5.863B	7.171B	8.701B
Interest Income	343.000M	415.000M	365.000M	157.000M	36.000M	59.000M	274.000M	343.000M
Interest Expense	1.357B	1.271B	1.146B	962.000M	806.000M	831.000M	893.000M	772.000M
Other Income/Expense	-2.419B	-285.000M	-1.065B	-1.838B	680.000M	315.000M	-755.000M	-230.000M
Net Income	18.254B	17.117B	365.000M	14.519B	13.049B	7.067B	9.843B	6.220B
Income Tax Expense	2.804B	2.803B	1.512B	1.918B	1.521B	1.340B	1.565B	2.508B
Net Profit Margin	28.1%	26.7%	0.6%	24.5%	26.8%	17.0%	25.2%	14.7%
EBITDA	29.324B	25.706B	6.907B	21.315B	17.899B	10.180B	11.374B	13.992B
EBITDA Margin	45.2%	40.1%	11.5%	36.0%	36.8%	24.5%	29.1%	33.1%
Depreciation & Amortization	5.838B	4.499B	3.872B	3.909B	3.214B	3.486B	3.310B	4.519B
EPS Basic	7.30	6.76	0.14	5.73	5.16	2.79	3.84	2.40
EPS Diluted	7.28	6.74	0.14	5.71	5.14	2.78	3.82	2.32
Shares Outstanding	2.502B	2.532B	2.607B	2.532B	2.530B	2.530B	2.565B	2.593B
Diluted Shares Outstanding	2.507B	2.541B	2.547B	2.542B	2.538B	2.541B	2.580B	2.679B

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.

About Merck & Co., Inc.

Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.

Rahway, NJ

73,000 employees

www.merck.com

Healthcare / Drug Manufacturers - General

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO: Robert Davis

View full financials